Multi-omics cluster defines the subtypes of CRC with distinct prognosis and tumor microenvironment

被引:6
作者
Ma, Yuan [1 ]
Li, Jing [1 ]
Zhao, Xu [1 ]
Ji, Chao [1 ]
Hu, Weibin [1 ]
Ma, Yanfang [1 ]
Qu, Fengyi [1 ]
Sun, Yuchen [1 ]
Zhang, Xiaozhi [1 ]
机构
[1] Xi An Jiao Tong Univ, Dept Radiat Oncol, Affiliated Hosp 1, Yanta West Rd 277, Xian 710061, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Colorectal cancer; Multi-omics profile; Molecular subtype; Prognostic marker; MID2; COLORECTAL-CANCER; BREAST-CANCER; SIGNATURES; GENES;
D O I
10.1186/s40001-024-01805-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Colorectal cancer (CRC) is a complex malignancy characterized by diverse molecular profiles, clinical outcomes, and limited precision in prognostic markers. Addressing these challenges, this study utilized multi-omics data to define consensus molecular subtypes in CRC and elucidate their association with clinical outcomes and underlying biological processes.Methods Consensus molecular subtypes were obtained by applying ten integrated multi-omics clustering algorithms to analyze TCGA-CRC multi-omics data, including mRNA, lncRNA, miRNA, DNA methylation CpG sites, and somatic mutation data. The association of subtypes with prognoses, enrichment functions, immune status, and genomic alterations were further analyzed. Next, we conducted univariate Cox and Lasso regression analyses to investigate the potential prognostic application of biomarkers associated with multi-omics subtypes derived from weighted gene co-expression network analysis (WGCNA). The function of one of the biomarkers MID2 was validated in CRC cell lines.Results Two CRC subtypes linked to distinct clinical outcomes were identified in TCGA-CRC cohort and validated with three external datasets. The CS1 subtype exhibited a poor prognosis and was characterized by higher tumor-related Hallmark pathway activity and lower metabolism pathway activity. In addition, the CS1 was predicted to have less immunotherapy responder and exhibited more genomic alteration compared to CS2. Then a prognostic model comprising five genes was established, with patients in the high-risk group showing substantial concordance with the CS1 subtype, and those in the low-risk group with the CS2 subtype. The gene MID2, included in the prognostic model, was found to be correlated with epithelial-mesenchymal transition (EMT) pathway and distinct DNA methylation patterns. Knockdown of MID2 in CRC cells resulted in reduced colony formation, migration, and invasion capacities.Conclusion The integrative multi-omics subtypes proposed potential biomarkers for CRC and provided valuable knowledge for precision oncology.
引用
收藏
页数:17
相关论文
共 62 条
  • [1] The repertoire of mutational signatures in human cancer
    Alexandrov, Ludmil B.
    Kim, Jaegil
    Haradhvala, Nicholas J.
    Huang, Mi Ni
    Ng, Alvin Wei Tian
    Wu, Yang
    Boot, Arnoud
    Covington, Kyle R.
    Gordenin, Dmitry A.
    Bergstrom, Erik N.
    Islam, S. M. Ashiqul
    Lopez-Bigas, Nuria
    Klimczak, Leszek J.
    McPherson, John R.
    Morganella, Sandro
    Sabarinathan, Radhakrishnan
    Wheeler, David A.
    Mustonen, Ville
    Getz, Gad
    Rozen, Steven G.
    Stratton, Michael R.
    [J]. NATURE, 2020, 578 (7793) : 94 - +
  • [2] Understanding cell-cell communication and signaling in the colorectal cancer microenvironment
    AlMusawi, Shaikha
    Ahmed, Mehreen
    Nateri, Abdolrahman S.
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2021, 11 (02):
  • [3] Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer
    Amatu, Alessio
    Sartore-Bianchi, Andrea
    Moutinho, Catia
    Belotti, Alessandro
    Bencardino, Katia
    Chirico, Giuseppe
    Cassingena, Andrea
    Rusconi, Francesca
    Esposito, Anna
    Nichelatti, Michele
    Esteller, Manel
    Siena, Salvatore
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2265 - 2272
  • [4] A High Degree of LINE-1 Hypomethylation Is a Unique Feature of Early-Onset Colorectal Cancer
    Antelo, Marina
    Balaguer, Francesc
    Shia, Jinru
    Shen, Yan
    Hur, Keun
    Moreira, Leticia
    Cuatrecasas, Miriam
    Bujanda, Luis
    Dolores Giraldez, Maria
    Takahashi, Masanobu
    Cabanne, Ana
    Edmundo Barugel, Mario
    Arnold, Mildred
    Luis Roca, Enrique
    Andreu, Montserrat
    Castellvi-Bel, Sergi
    Llor, Xavier
    Jover, Rodrigo
    Castells, Antoni
    Boland, C. Richard
    Goel, Ajay
    [J]. PLOS ONE, 2012, 7 (09):
  • [5] A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation
    Calegari, M. A.
    Inno, A.
    Monterisi, S.
    Orlandi, A.
    Santini, D.
    Basso, M.
    Cassano, A.
    Martini, M.
    Cenci, T.
    de Pascalis, I.
    Camarda, F.
    Barbaro, B.
    Larocca, L. M.
    Gori, S.
    Tonini, G.
    Barone, C.
    [J]. BRITISH JOURNAL OF CANCER, 2017, 116 (10) : 1279 - 1286
  • [6] Turning foes to friends: targeting cancer-associated fibroblasts
    Chen, Xueman
    Song, Erwei
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (02) : 99 - 115
  • [7] Clustering analysis revealed the autophagy classification and potential autophagy regulators' sensitivity of pancreatic cancer based on multi-omics data
    Chen, Yonghao
    Meng, Jialin
    Lu, Xiaofan
    Li, Xiao
    Wang, Chunhui
    [J]. CANCER MEDICINE, 2023, 12 (01): : 733 - 746
  • [8] Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer
    Du, Mulong
    Gu, Dongying
    Xin, Junyi
    Peters, Ulrike
    Song, Mingyang
    Cai, Guoshuai
    Li, Shuwei
    Ben, Shuai
    Meng, Yixuan
    Chu, Haiyan
    Chen, Lianmin
    Wang, Qianghu
    Zhu, Lingjun
    Fu, Zan
    Zhang, Zhengdon
    Wang, Meilin
    [J]. CELL REPORTS MEDICINE, 2023, 4 (03)
  • [9] Worldwide burden of colorectal cancer: a review
    Favoriti, Pasqualino
    Carbone, Gabriele
    Greco, Marco
    Pirozzi, Felice
    Pirozzi, Raffaele Emmanuele Maria
    Corcione, Francesco
    [J]. UPDATES IN SURGERY, 2016, 68 (01) : 7 - 11
  • [10] Large-scale public data reuse to model immunotherapy response and resistance
    Fu, Jingxin
    Li, Karen
    Zhang, Wubing
    Wan, Changxin
    Zhang, Jing
    Jiang, Peng
    Liu, X. Shirley
    [J]. GENOME MEDICINE, 2020, 12 (01)